RBWH11

RBWH11 (0.375-200 μM; 18-24 h) potently inhibits the growth of all tested ESKAPE pathogens, including multidrug-resistant strains, with MIC values ranging from 1.5 to 18 μM^[1].
RBWH11 (24-48 h) exhibits bactericidal activity against S. aureus ATCC25923 and P. aeruginosa PAO1^[1].
RBWH11 (2.3-36 μM; 9-144 μM) dose-dependently permeabilizes the inner membranes of S. aureus ATCC25923 and P. aeruginosa PAO1, leading to increased PI uptake and bacterial membrane compromise^[1].
RBWH11 (72 μM; up to 60 min; 90 min) disrupts the membrane integrity of P. aeruginosa PAO1, causing membrane morphological changes, colocalization with the membrane, and eventual bacterial death^[1].
RBWH11 (2.3-36 μM; 9-144 μM; 90 min; 24 h) dose-dependently eradicates preformed biofilms of S. aureus ATCC25923 and P. aeruginosa PAO1, with up to ~50% and ~60% eradication at the highest tested concentrations, respectively^[1].
RBWH11 (8-24 h) exhibits moderate stability in human plasma, with ~60-70% intact peptide remaining after 8 h and ~35-44% remaining after 24 h of incubation at 37 °C^[1].
RBWH11 is biocompatible with HEK293 cells, THP-1-derived macrophages, and L929 fibroblasts, exhibiting low cytotoxicity and favorable ratios between non-toxic and active concentrations relative to its antimicrobial activity^[1].
RBWH11 (30-60 μM; 1-3 h) exhibits negligible hemolytic activity against rodent and human RBCs at concentrations up to 60 μM, with favorable ratios between non-toxic and active concentrations^[1].
RBWH11 (24-48 h) promotes L929 fibroblast migration, accelerating artificial wound closure in an in vitro scratch assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.